Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial.
Benjamin MovsasJoseph P RodgersMohamed A ElshaikhAlvaro A MartinezGerard C MortonDaniel J KraussDi YanDeborah E CitrinBruce W HershatterJeff M MichalskiRodney J EllisVivek S KavadiElizabeth M GoreGary S GustafsonCraig A SchulzVikram M VelkerAdam C OlsonFabio L CuryMichael A PapagikosTheodore G KarrisonHoward M SandlerDeborah Watkins BrunerPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Compared with dose-escalated RT alone, adding TAS demonstrated clinically meaningful declines only in EPIC hormonal and sexual domains. However, even these PRO differences were transient, and there were no clinically meaningful differences between arms by 1 year.